[Differences between EGFR Exon 19 Deletion and Exon 21 L858R Point Mutation, Frequently Detected EGFR Mutations in Patients with Non-Small Cell Lung Cancer, from a Molecular Biology Viewpoint]

Takashi Kohno; Tomoko Matsui; Sotaro Enatsu

[Differences between EGFR Exon 19 Deletion and Exon 21 L858R Point Mutation, Frequently Detected EGFR Mutations in Patients with Non-Small Cell Lung Cancer, from a Molecular Biology Viewpoint]

Gan To Kagaku Ryoho. 2021 Dec;48(12):1463-1467.

[Article in Japanese]

Authors

Takashi Kohno¹, Tomoko Matsui, Sotaro Enatsu

Affiliation

¹ Division of Genome Biology, National Cancer Center Research Institute.

PMID: 34911913

Abstract

Epidermal growth factor receptor(EGFR)is a transmembrane receptor tyrosine kinase that plays an important role in regulating the growth and progression of cancer via signalling pathways. This review summarizes the differences in EGFR kinase structural changes, stability of active forms, and phosphorylation inhibitory effects of EGFR tyrosine kinase inhibitors between the exon 19 deletion mutation and the exon 21 L858R point mutation, which are frequently detected EGFR mutations in patients with non-small cell lung cancer.

Publication types

Review

MeSH terms

Carcinoma, Non-Small-Cell Lung* / drug therapy
Carcinoma, Non-Small-Cell Lung* / genetics
ErbB Receptors / genetics
Exons / genetics
Humans
Lung Neoplasms* / drug therapy
Lung Neoplasms* / genetics
Molecular Biology
Mutation
Point Mutation
Protein Kinase Inhibitors / therapeutic use

Substances

Protein Kinase Inhibitors
EGFR protein, human
ErbB Receptors